Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19.

Sharma T, Mondal T, Khan S, Churqui MP, Nyström K, Thombare K, Baig MH, Dong J

Arch Microbiol 206 (2) 69 [2024-01-19; online 2024-01-19]

The nuclear export protein 1 (XPO1) mediates the nucleocytoplasmic transport of proteins and ribonucleic acids (RNAs) and plays a prominent role in maintaining cellular homeostasis. XPO1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses. In our earlier study, we proved the inhibition of XPO1 as a therapeutic strategy for managing SARS-COV-2 and its variants. In this study, we have utilized pharmacophore-assisted computational methods to identify prominent XPO1 inhibitors. After several layers of screening, a few molecules were shortlisted for further experimental validation on the in vitro SARS-CoV-2 cell infection model. It was observed that these compounds reduced spike positivity, suggesting inhibition of SARS-COV-2 infection. The outcome of this study could be considered further for developing novel antiviral therapeutic strategies against SARS-CoV-2.

Category: Drug Discovery

Category: Genomics & transcriptomics

Category: Proteins

Funder: VR

Type: Journal article

PubMed 38240823

DOI 10.1007/s00203-023-03761-z

Crossref 10.1007/s00203-023-03761-z

pii: 10.1007/s00203-023-03761-z

Publications 9.5.0